Heberprot-P benefits more than 31,000 Cubans Orfilio Peláez Cuba has reduced the risk of amputation caused by ulcers in diabetics by more than 78% thanks to the implementation of a comprehensive program across all provinces, directed toward treating patients suffering from the problem, including through the use of Heberprot-P. Developed by specialists from the Cuban Center for Genetic Engineering and Biotechnology (CIBG), in collaboration with other entities, Heberprot-P is the only drug worldwide, capable of enhancing the healing of such complex lesions, and which has benefited more than 31,000 Cubans. In addition, for three consecutive years the diabetes mortality rate in the country has continued to decrease, while 84% of suffers reach the same life expectancy as non-diabetic Cubans (around 78 years). These remarkable results will be presented at the International Congress on the Control of Diabetes, which will be take place in Varadero from December 10-12. According to Mailyn Palmero Molina, member of the event organizing committee, confirmed to attend is Mr. Michael Hirst, President of the International Diabetes Federation (IDF), an organization which includes some 230 national associations from 170 countries.
Posted on: Tue, 23 Sep 2014 16:50:06 +0000
Trending Topics
Recently Viewed Topics
© 2015